Chestnut Hill Hospital enrolls patients for Covid-19 research study
Chestnut Hill Hospital— Tower Health recently enrolled three Covid-19 patients in the “ImmunoPhenotyping Assessment in a Covid-19 Cohort” study, or IMPACC, that aims to advance development of effective treatments for Covid-19. Researchers are tracking adult Covid-19 patients at all seven Tower Health facilities as part of the national study of approximately 2,000 patients undergoing treatment for Covid-19 in a hospital. Currently, Tower Health has 41 patients enrolled, and the goal is 100 study participants.
Tower Health is among 10 leading medical institutions nationwide embarking on the IMPACC study that is funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases. IMPACC will help determine how certain immunological measures correspond to, or may even predict, the clinical severity of Covid-19. Participants are followed for 12 months after their hospitalization to assess how well they recover and whether they develop durable immunity to the virus. Tower Health is collaborating with the Drexel University College of Medicine, Clinical Research Unit in collecting and analyzing data.
Participating patients are enrolled within 48 hours of admission and then followed by researchers and clinical teams who collect blood and nasal swab samples from study participants throughout their hospitalization and at subsequent outpatient visits over the next 12 months. Biologic samples from study participants are analyzed for various aspects of their immune response to the virus, with the goal of understanding why some patients with Covid-19 worsen while other patients recover. As participants recover, investigators will continue to evaluate their immune responses to discover any factors that may provide long-term protection against re-infection.
“This study is one of many clinical projects working to better understand how this novel disease affects people differently and to determine optimal ways to treat Covid-19 patients,” said Bevin Dolan, MD, Chief, Section of Infectious Disease at Chestnut Hill Hospital. “Hopefully, data collected in the IMPACC study will help inform recommendations for Covid-19 care and identify new targets and optimal timing for experimental treatments.”
“Our goal is to identify biomarkers that can predict the severity of symptoms, guide treatment and help us provide every Covid-19 patient the best care possible,” said principal investigator Charles B. Cairns, MD, FACEP, FAAEM, FAHA, the Walter H. and Leonore Annenberg Dean of Drexel University’s College of Medicine and senior vice president for Medical Affairs. “This clinical study also reflects the extraordinary value of the Drexel – Tower partnership by leveraging our extensive expertise in infectious diseases to advance new insights about the immune responses of Covid-19 patients, including long-term consequences of this devastating disease.”
For more information on this study visit ClinicalTrials.gov.
Located in the Chestnut Hill section of Philadelphia and a member of Tower Health, Chestnut Hill Hospital is a 148-bed, community-based, university-affiliated, teaching hospital committed to excellent patient-centered care. Chestnut Hill Hospital provides a full range of inpatient and outpatient, diagnostic and treatment services for people in northwest Philadelphia and eastern Montgomery County. With more than 300 board-certified physicians, Chestnut Hill Hospital’s specialties include minimally invasive laparoscopic and robotic surgery, cardiology, gynecology, oncology, orthopedics, urology, family practice and internal medicine. Chestnut Hill Hospital is accredited by The Joint Commission and is affiliated with university-hospitals in Philadelphia for heart and stroke care and residency programs.
For more information, visit www.towerhealth.org.